| Title | Modulation of Cell-adhesive Activity of Fibronectin by the Alternatively Spliced EDA Segment |
|-------|-----------------------------------------------------------------------------------------|
| Author(s) | Manabe, Ri-ichiroh; Oh-e, Naoko; Maeda, Toshinaga; Fukuda, Tomohiko; Sekiguchi, Kiyotoshi |
| Citation | Journal of Cell Biology. 139(1) P.295–P.307 |
| Issue Date | 1997-10 |
| Text Version | publisher |
| URL | http://hdl.handle.net/11094/71820 |
| DOI | 10.1083/jcb.139.1.295 |
| Note | Osaka University Knowledge Archive : OUKA |

Osaka University Knowledge Archive : OUKA
https://ir.library.osaka-u.ac.jp/repo/ouka/all/
Modulation of Cell-adhesive Activity of Fibronectin by the Alternatively Spliced EDA Segment

Ri-ichiroh Manabe, Naoko Oh-e, Toshinaga Maeda, Tomohiko Fukuda, and Kiyotoshi Sekiguchi
Research Institute, Osaka Medical Center for Maternal and Child Health, Izumi, Osaka 590-02, Japan

Abstract. Fibronectin (FN) has a complex pattern of alternative splicing at the mRNA level. One of the alternatively spliced segments, EDA, is prominently expressed during biological processes involving substantial cell migration and proliferation, such as embryonic development, malignant transformation, and wound healing. To examine the function of the EDA segment, we overexpressed recombinant FN isoforms with or without EDA in CHO cells and compared their cell-adhesive activities using purified proteins. EDA+ FN was significantly more potent than EDA− FN in promoting cell spreading and cell migration, irrespective of the presence or absence of a second alternatively spliced segment, EDB. The cell spreading activity of EDA+ FN was not affected by antibodies recognizing the EDA segment but was abolished by antibodies against integrin α5 and β1 subunits and by Gly-Arg-Gly-Asp-Ser-Pro peptide, indicating that the EDA segment enhanced the cell-adhesive activity of FN by potentiating the interaction of FN with integrin α5β1. In support of this conclusion, purified integrin α5β1 bound more avidly to EDA+ FN than to EDA− FN. Augmentation of integrin binding by the EDA segment was, however, observed only in the context of the intact FN molecule, since the difference in integrin-binding activity between EDA+ FN and EDA− FN was abolished after limited proteolysis with thermolysin. Consistent with this observation, binding of integrin α5β1 to a recombinant FN fragment, consisting of the central cell-binding domain and the adjacent heparin-binding domain Hep2, was not affected by insertion of the EDA segment. Since the insertion of an extra type III module such as EDA into an array of repeated type III modules is expected to rotate the polypeptide up to 180° at the position of the insertion, the conformation of the FN molecule may be globally altered upon insertion of the EDA segment, resulting in an increased exposure of the RGD motif in III10 module and/or local unfolding of the module. Our results suggest that alternative splicing at the EDA exon is a novel mechanism for up-regulating integrin-binding affinity of FN operating when enhanced migration and proliferation of cells are required.

Fibronectins (FNs) are multifunctional adhesive glycoproteins present in the extracellular matrix and various body fluids. They provide excellent substrates for cell adhesion and spreading, thereby promoting cell migration during embryonic development, wound healing, and tumor progression (for review see Hynes, 1990). FNAs are disulfide-bonded dimers of two closely related subunits, each consisting of three types of homologous repeating modules termed types I, II, and III (Petersen et al., 1983). These repeats are organized into a series of functional domains that bind to integrins, collagens, heparin and heparan sulfate, fibrin, and FNAs themselves.

Address all correspondence to Kiyotoshi Sekiguchi, Research Institute, Osaka Medical Center for Maternal and Child Health, 840 Murodo, Izumi, Osaka 590-2, Japan. Tel.: (81) 725-56-1220 (ext. 5401). Fax: (81) 725-57-3021. e-mail: j61639@center.osaka-u.ac.jp

Abbreviations used in this paper: CCBD, central cell-binding domain; FN, fibronectin; GST, glutathione-S-transferase; MBP, maltose-binding protein; RGD, Arg-Gly-Asp.

FNs can interact with cells at three distinct regions: the central cell-binding domain (CCBD), the COOH-terminal heparin-binding domain (Hep2), and the type III-connecting segment (IICS) including the CS1 region (Yamada, 1991). CCBD is the major cell-adhesive domain of FN and contains the Arg-Gly-Asp (RGD) motif that is recognized by members of the integrin family of cell adhesion receptors, including α5β1, αvβ3, αvβ5, αvβ6, αIIbβ3, and α8β1 (Ruoslahti and Pierschbacher, 1987; Hynes, 1992; Müller et al., 1995; Chen et al., 1996). α5β1 is the primary FN receptor in many cell types and differs from the αv- and αIIb-containing integrins in that it requires not only the IIIa module containing the RGD motif, but also the IIIi module for binding to FN (Aota et al., 1991). Recently, a short sequence Pro-His-Ser-Arg-Asn (PHSRN) has been identified as a synergistic motif in FN for binding to integrins α5β1 (Aota et al., 1994) and αIIbβ3 (Boudewit et al., 1994). Interaction of α5β1 with CCBD has been shown to transduce signals that regulate cell proliferation, differentiation, and apoptosis (Giancotti and Ruoslahti,
although the molecular basis for integrin-mediated signaling is not well understood. The importance of the FN-integrin α5β1 interaction has been demonstrated in mice by the embryonic lethality of deficiencies in either FN or α5β1 expression (George et al., 1993; Yang et al., 1993).

FNs purified from different sources appear to be slightly different with respect to subunit sizes (Yamada and Kennedy, 1979). The heterogeneity of FN subunits arises mainly from alternative splicing of a primary transcript at three distinct regions termed EDA, EDB, and IIICS (Schwarzbauer et al., 1983, 1987; Kornblihtt et al., 1984; Zardi et al., 1987). The EDA and EDB segments are each encoded by a single exon and can each comprise an intact type III repeat (Schwarzbauer et al., 1987). The IIICS segment, on the other hand, consists of five distinct variants due to exon subdivision (Kornblihtt et al., 1985; Sekiguchi et al., 1986). Up to 20 different FN subunits may result from alternative splicing involving these three segments. Many lines of evidence indicate that alternative splicing at these regions is regulated in a tissue-specific and oncoderpendent manner. For example, plasma FN produced by adult hepatocytes contains neither EDA nor EDB segments in both subunits and lacks the entire IIICS in one of the subunits, although cultured fibroblasts typically produce some FNs containing the EDA and/or EDB segments (Kornbluth et al., 1984; Sekiguchi et al., 1986; Zardi et al., 1987). FNs expressed in fetal and tumor tissues contain a greater percentage of EDA and EDB segments than those expressed in normal adult tissues (Oyama et al., 1989a,b; 1993; Carnemolla et al., 1989; ffrench-Constant and Hynes, 1989). Increased expression of FNs containing the EDA and/or EDB segments has also been observed during wound healing (ffrench-Constant et al., 1989).

Despite accumulated evidence for regulated expression of EDA- and/or EDB-containing FNs in vivo, the biological functions of these isoforms are poorly understood. Many efforts have been made to detect functional differences between plasma FN and FNs purified from conditioned medium of cultured fibroblasts, collectively referred to as “cellular FN,” and to elucidate the function of alternatively spliced coding regions. No clear differences have been reported, however, between plasma and cellular FNs in their abilities to promote cell adhesion and spreading, except that these two forms differ in their solubilities (for review see ffrench-Constant, 1995). Since cellular FN is a mixture of heterodimers of several different subunits differing with respect to the presence or absence of the EDA and/or EDB segments, failure to detect functional differences could be due to heterogeneity of cellular FN. To overcome this problem, Guan et al. (1990) expressed, in mouse lymphoid cells, various recombinant isoforms of rat FNs, each containing a different combination of the three alternatively spliced regions, and compared the biological activities of the homogenous recombinant proteins. No clear differences were, however, observed among the abilities of FN isoforms to promote cell adhesion, spreading, and migration, except for minor differences in the ability to assemble into the preexisting extracellular matrix.

Recently, we constructed an expression vector encoding full length human plasma FN that lacks both the EDA and EDB segments but includes IIICS and overexpressed this recombinant isofrom in human tumor cells to restore the pericellular FN matrix around the tumor cells (Akamatsu et al., 1996). In the present study, we constructed two additional expression vectors encoding human FNs containing either both the EDA and EDB segments or the EDA segment alone and overexpressed these FN isoforms in CHO cells to compare the biological activities of three different forms of recombinant FNs (i.e., EDA+/EDB−, EDA−/ EDB+, and EDA+/EDB+ FNs) using purified homodimeric proteins. Our results showed that the EDA+ isofrom was more than twice as effective as the EDA− isofrom in promoting cell spreading and cell migration, irrespective of the presence or absence of the EDB segment. Increased cell adhesion and migration on the EDA+ FN substrate was apparently due to an increase in the binding affinity of integrin α5β1. We discuss molecular mechanisms and implications of the EDA-dependent enhanced integrin binding on the basis of conformational modulation of the FN molecule by insertion of the EDA segment.

Materials and Methods

cDNA Construction

cDNA expression vectors for the full length human FN isoforms differing in the presence or absence of the EDA and/or EDB segments were constructed by modifying pAIPFN that encodes a full length FN lacking both extra type III repeats (Akamatsu et al., 1996). pAIPFN was first modified to delete the BamHI site located 5′ to the ATO initiation codon as follows: pAIPFN was cleaved with BamHI and EcoRV and the resulting 2411-bp cDNA fragment encoding the signal sequence of human protein C inhibitor and NH2-terminal FN sequence was filled in using the Klenow fragment of DNA polymerase I and subcloned into the EcoRV site of pBluescript II (Stratagene, La Jolla, CA). The insert was excised as 1708-bp HindIII–Sall fragment and ligated into HindIII–Sall-cleaved pAIPFN, yielding the expression vector (pAIFNC) for the FN isoform lacking both the EDA and EDB segments. pAIFNC is identical to pAIPFN except for the absence of the S′ BamHI site.

For construction of the expression vector encoding the FN isoform containing EDA but not EDB, a BamHI–XbaI fragment of pHCF5 (provided by Dr. K. Ichihara-Tanaka, Fujita Health University, Toyoake, Japan) that encodes the EDA segment and its flanking region (Arg1449–Ser1200) was cloned into the BamHI site of pUC119 in tandem with a XbaI–BamHI fragment of pAIFNC that comprises the sequence encoding Ser2256–Glu1446 and the 3′ untranslated sequence including a polyadenylation signal. Amino acids are numbered from the NH2-terminal pyroglutamic acid in the mature protein (Petersen et al., 1989). The whole insert was then excised with BamHI and inserted into BamHI-cleaved pAIFNC. The resulting cDNA expression vector for the EDA+/EDB− FN was designated pAIFNAC.

For construction of the expression vector encoding the FN isoform containing both EDA and EDB segments, a KpnI–SpeI fragment encoding Val127–Arg449 without the EDB segment was excised from pHCF93 (provided by Dr. K. Ichihara-Tanaka), filled in with the Klenow fragment of DNA polymerase I, and subcloned into the HincII site of pHCF93 encoding Ser1200–Val449 including the EDB segment. The resulting plasmid was linearized with SacI and ligated with the SacI fragment of pHCF93 encoding Ser1050–Ser1200, yielding pHCF93B+. The whole insert of pHCF93B+ was excised with SacI and BamHI, and ligated to SacI–BamHI-cleaved pAIFNC. The plasmid was then recut with BamHI and ligated with the BamHI fragment excised from pAIFNAC (encoded Arg449 through the SV40 polyadenylation signal). The resulting cDNA expression vector for EDA+/EDB+ FN was designated pAIFNABC.

The Journal of Cell Biology, Volume 139, 1997 296
Cell Culture

Human HT1080 fibrosarcoma cells, human WI-38 fibroblasts, rat NRK cells, and hamster CHO-K1 cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). Mouse L cells were provided by Dr. Hiroshi Teraoka, Shionogi Research Laboratory, Shionogi and Co., Ltd., Osaka, Japan. The dihydrofolate reductase-deficient CHO cell line, CHO DG44, was provided by Dr. Lawrence Chasin (Columbia University, New York) and used for the production of recombinant FNs. HT1080, WI-38, NRK, and L cells were grown in DME supplemented with 10% FBS. CHO cell lines were maintained in α-minimal essential medium containing ribonucleosides and deoxyribonucleosides (GIBCO BRL, Gaithersburg, MD) plus 10% FBS.

DNA Transfection and Selection of Stable Transfectants
cDNA expression vectors were cotransfected into CHO DG44 cells with pGEMSVdhfr encoding a dihydrofolate reductase minigene (provided by Dr. Hiroshi Teraoka, Shionogi Research Laboratory, Shionogi and Co., Ltd., Osaka, Japan) by the calcium-phosphate precipitation method (Chen and Okayama, 1987). Selection of stable transfectants and subsequent amplification of the introduced cDNA were carried out as described (Kaufman, 1989). Levels of recombinant FN expression were routinely monitored by dot immunosassay of the culture supernatants with the anti-human FN mAb FN8-12 (Matsuyama et al., 1994). Levels of recombinant FN expression in clones thus selected were ~40 times higher than that of endogenous FN expression in untransfected CHO DG44 cells.

Purification of FNs

CHO transfectants overexpressing recombinant human FNs were cultured in α-minimal essential medium with 1% FN-depleted FBS. FN-depleted FBS was prepared by passing the bacterial lysate by gelatin-affinity column twice. The culture supernatants were subjected to affinity chromatography using gelatin-Sepharose (Pharmacia Biotech, Uppsala, Sweden). Plasma and cellular FNs were purified as described previously (Sekiguchi et al., 1985). Typical yields of recombinant FNs were 4–6 mg/liter of conditioned media. In some experiments, gelatin-affinity-purified FNs were further purified by ion exchange chromatography on a HiTrap-Q column (Pharmacia Biotech).

Antibodies and Peptides

mAbs against integrin α5 and β1 subunits, 8F1 and 4G2, were established in our laboratory by fusion of SP2/0 myeloma cells with the spleen cells of BALB/c mice immunized with integrin α5β1 purified from human aorta. 8F1 and 4G2 inhibit binding of integrin α5β1 to FN as well as attachment and spreading of HT1080 cells on FN-coated substrata. mAbs against human FN, 15E, and 17C were also established in our laboratory using human plasma FN as immunogen. 15E and 17C recognize epitopes on CCBD and the Hep2 domain, respectively. mAbs against the human integrin α4 subunit (SG73; Miyake et al., 1992) and heparan sulfate (HepSS-1) were obtained from Seikagaku Corp. (Tokyo, Japan); mAb against human integrin αβ3 (LM609) was from Chemicon International, Inc. (Temecula, CA); mAbs against human FN (FN8-12 and FN30-8) were from Takara Shuzo (Kyoto, Japan); HRP-conjugated mAbs against human FN (OAL115) from Hisanobu Hirano (Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan); mAbs against EDA (IST-9; Borsi et al., 1987) and against FN containing the EDB segment (BC-1) from Dr. Luigino Zardi (Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy); another mAb against EDA (HHS01; Hirano et al., 1992) from Eiji Sakashita (Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan). Polyclonal antibodies against human FN were raised in rabbits by repeated immunization with purified human plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant.

SDS-PAGE and Immunoblot Analysis

SDS-PAGE was performed as described by Laemmli (1970). Purified FNs were separated on 6% polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were stained with mAbs against human FN using ECL reagents (Amersham Corp., Arlington Heights, IL).

Cell Spreading Assay

Cell spreading assays were performed using 96-well microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) coated with various concentrations of recombinant FNs and blocked with 1% BSA. Amounts of recombinant FNs immobilized on plates were determined by ELISA using anti–human FN mAbs and anti-FN antibodies. The 96-well plates coated with recombinant FNs and blocked with 1% BSA were incubated in DME containing 0.2% BSA and mAbs against human FN (OAL115) from Hisanobu Hirano (Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan); mAbs against EDA (IST-9; Borsi et al., 1987) and against FN containing the EDB segment (BC-1) from Dr. Luigino Zardi (Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy); another mAb against EDA (HHS01; Hirano et al., 1992) from Eiji Sakashita (Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan). Polyclonal antibodies against human FN were raised in rabbits by repeated immunization with purified human plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant. The polyclonal antibody against human FN was raised in rabbits by repeated immunization with purified plasma FN emulsified in complete Freund's adjuvant.

MBP- and GST-Fusion Proteins

Two cDNAs encoding the III13 and III12 modules of human FN with or without the EDA segment were amplified by reverse transcription PCR from mRNA extracted from WI-38 human fibroblasts using forward and reverse primers tagged with BamHI and SalI sites, respectively. The primers used were: 5′-AAAGTGGATCCGAAAAATGCAAC- CATCC-3′ (forward) and 5′-AAAGTGGATCCGAAAAATGCAAC- CATCC-3′ (reverse), where restriction sites and the stop codon are indicated with bold and italic characters, respectively. PCR-amplified fragments were cloned into the BamHI and SalI sites of pMAL-c2 and pMAL-c2T (Pharmacia Biotech) and was obtained as E.coli strain BL21, and the resulting GST fusion proteins (designated GST-CAH and GST-CH; see Fig. 1) were purified on glutathione Sepharose columns (Pharmacia Biotech) as suggested by the manufacturer, followed by ion exchange chromatography using a HiTrapQ column. The GST fusion protein containing only CCBD, designated GST-C, was prepared in the same manner except that the cDNA encoding fragment CCBD was amplified by PCR using 5′-TACATCTTCCCTGGGAATGTGACCAATTTGGATTTCCTCGAC-3′ (forward) and 5′-ACGCGTCGACCATTAATGCTTACATCTTCCCTGGGAATGTGACCAATTTGGATTTCCTC- TTTTTCFCCAAACTC-3′ (reverse), where the bold and italic characters indicate the restriction sites (SmaI and SalI) and stop codon, respectively, and the underline denotes a tag sequence derived from the Δ2 region of human FN (Sekiguchi and Titani, 1989). cDNA fragments were cleaved with BamHI and SalI and cloned into pGEX-T1 (Pharmacia Biotech). The plasmids were expressed in the E. coli strain BL21, and the resulting GST fusion proteins (designated GST-CAH and GST-CH; see Fig. 1) were further purified on glutathione Sepharose columns (Pharmacia Biotech) as suggested by the manufacturer. Selection of stable transfectants and subse-}

Manabe et al. Functional Modulation of Fibronectin by EDA Domain

297
with DME, and attached cells were fixed with 3.7% formaldehyde and then stained with Giemsa. Cells adopting a well spread morphology (i.e., cells that had become flattened with the long axis more than twice the diameter of the nucleus) were counted per square millimeter.

In some experiments, recombinant FNs were immobilized onto 96-well plates via the anti-human FN mAb FNS-12 which had been precoated on the plates. The amounts of the recombinant FNs captured on plates were determined by ELISA using the anti-FN mAb OAL115.

**Treatment of Cells with Glycosidases**

HT1080 cells were resuspended in DME containing 0.1% BSA at 3 × 10^5 cells/ml in the presence or absence of 0.1 U/ml of heparitinase I, heparinase, or chondroitinase ABC (Seikagaku Corp.). Cell suspensions were incubated for 30 min at 37°C before the cell spreading assay.

**Flow Cytometry**

HT1080 cells were stained with the anti-heparan sulfate mAb HepS-1 (isotype, IgM), followed by incubation with FITC-conjugated goat antimouse IgM, and then analyzed using a FACSScan™ flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA).

**Purification of α5β1 and αvβ3 Integrins**

Purification of integrin receptors and reconstitution of purified integrins into liposomes were carried out according to Pytelia et al. (1987). Briefly, fresh human placental tissue was extracted with TBS(+) (25 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM CaCl₂, and 1 mM MgCl₂) containing 100 mM octylglucoside and 1 mM PMSF. The extract was applied on a series of Sepharose affinity columns conjugated with either GRGDSP peptide (for purification of αvβ3) or the 155-kD/145-kD thermolysin fragments of human plasma FN (for purification of α5β1). Integrins bound to these affinity columns were eluted with TBS(-) containing GRGDSP peptide (250 μM/ml). Eluted integrins were further purified on a column of wheat germ lectin Sepharose (Pharmacia Biotech). Purified integrins (50 μg) were mixed with egg yolk phosphatidylcholine (50 μg) containing [3H]dipalmitoyl phosphatidylcholine (New England Nuclear, Boston, MA) in TBS(-) containing 50 mM octylglucoside and then dialyzed against >4,000 vol of TBS(-) at 4°C overnight. The reconstituted integrin liposomes were size fractionated on a Sepharose CL-4B column (Pharmacia Biotech) and used in the integrin liposome binding assay.

**Integrin Liposome Binding Assay**

Integrin liposomes in TBS(+) containing 0.2% BSA were added to microtiter wells precoated with recombinant FNs (20 μg/ml) or GST fusion fragments (20 or 80 μg/ml) and incubated for 6 h at room temperature. Amounts of recombinant FNs immobilized on wells were verified by ELISA using polyclonal antibody against CCBD. For inhibition assays, the integrin liposomes were preincubated with anti-integrin mAbs (10 μg/ml) or control IgG (20 μg/ml) or synthetic peptides (1 μM) for 30 min at room temperature before addition to FN- or fusion fragment-coated wells. The wells were washed with TBS(+), and bound liposomes were recovered in 1 N NaOH. The radioactivity of bound liposomes was quantitated using an Aloka LSC-3500 scintillation counter (Aloka Co., Ltd., Tokyo, Japan). In the binding assays using thermolysin-cleaved FNs as ligands, phosphoramidon (4 μg/ml) was included in the assay medium to inactivate thermolysin.

**Cell Migration Assay**

Thin plastic discs (ø 6 mm) were cut in half and coated with 0.01% poly-l-lysine (Sigma Chemical Co., St. Louis, MO) followed by blocking with 1% BSA. Plastic discs were placed in wells of 96-well microtiter plates that had been precoated with 5 μg/ml of recombinant FNs or 0.01% poly-l-lysine and then blocked with 1% BSA. HT1080 cells suspended in DME were seeded onto the plates at a density of 1 × 10^5 cells/well. After incubation at 37°C for 1.5 h, plastic discs were removed carefully, and the wells were gently washed with DME and photographed. Cells attached to the 96-well plates were further incubated for 12 h in DME to allow them to migrate into the open space left after removal of the discs. The cells were then fixed with 3.7% formaldehyde and stained with Giemsa. Cell motility was assessed by the distance of the outward migration, i.e., the distance between the positions of the cell front before and after cell migration. The

Figure 1. The structure of recombinant FNs and bacterially expressed fusion fragments. Modular structures of recombinant FNs are shown schematically on the basis of internally homologous modules termed types I, II, and III. The EDA and EDB segments are shown with filled rectangles, while the IIICS segment is shown by a hatched oval. All recombinant FNs contain the complete IIICS sequence of 120 amino acids. Functional domains that interact with heparin (Hep1, Hep2), fibrin (Fib1, Fib2), bacteria, collagen, and cell surface integrins (CCBD) are indicated above the schemes. Recombinant FN fragments encompassing different intervals of type III modules were produced as fusion proteins with either GST or MBP.

**Results**

**Construction of Expression Vectors Encoding FN Isoforms Differing in the Inclusion of EDA and/or EDB Segments**

Three human FN isoforms used in this study are illustrated in Fig. 1. These isoforms are identical except for the presence or absence of the EDA and/or EDB segments. All three include the complete IIICS sequence of 120 amino acids. FN isoforms were expressed as chimeric proteins with the signal sequence of human protein C inhibitor as described previously (Ichihara-Tanaka et al., 1990). The expression vectors for these isoforms were constructed by modifying the human FN expression vector pAIPFN (Aka-matsu et al., 1996) as described in Materials and Methods. The resulting FN isoforms are designated as follows: rFN(C), the isoform lacking both EDA and EDB segments; rFN(AC), the isoform containing EDA but lacking EDB; and rFN(BAC), the isoform containing both EDA and EDB segments.

**Expression and Purification of Recombinant FNs**

Expression vectors were cotransfected into CHO DG44 cells with a dihydrofolate reductase minigene, and the resulting stable transfectants were treated with increasing concentrations of methotrexate to amplify the introduced recombinant genes. Recombinant FN isoforms were purified from the conditioned media of methotrexate-resistant
transfectants by gelatin affinity chromatography. Typical yields of recombinant FNs were 4–6 mg/liter of conditioned medium. Since the concentration of hamster FN in the conditioned medium of untransfected CHO cells was 0.1–0.15 mg/liter, the fraction of contaminating hamster FN in the purified recombinant FNs should not exceed 4% of total protein.

Purified FNs gave single bands with apparent molecular masses of 220–250 kD upon SDS-PAGE under reducing conditions (Fig. 2A). The relative molecular masses of the recombinant FNs were in the order of rFN(BAC) > rFN(AC) > rFN(C), consistent size differences expected due to the presence or absence of the EDA and/or EDB segments. The recombinant FNs gave sharper bands in SDS-PAGE compared to native FNs purified from plasma (plasma FN) and from conditioned medium of cultured fibroblasts (cellular FN), confirming the homogeneity of the recombinant FNs. SDS-PAGE under nonreducing conditions showed that almost all of the recombinant FNs exist as dimers, as observed for plasma and cellular FNs (Fig. 2A). Presence or absence of the EDA and EDB segments were confirmed by immunoblot analysis (Fig. 2B).

Cell Adhesive Activity of Recombinant FNs

EDA+ FN isoforms have been shown to be expressed prominently in tissues where cells actively proliferate and migrate, such as those in embryos, tumors, and healing wounds. To explore the physiological functions of the EDA segment, we first compared the cell-adhesive activity of recombinant FNs with or without EDA. When HT1080 cells were incubated on substrates coated with recombinant FNs or with plasma or cellular FN, significant differences were seen in the numbers of cells attached to different forms of FNs (Fig. 3A). HT1080 cells attached in greater numbers to substrates coated with rFN(AC) or rFN(BAC) than to the substrate coated with rFN(C). A similar but less pronounced difference was observed between the substrates coated with plasma or cellular FNs. In addition to promoting more cell attachment, rFN(AC) and rFN(BAC) were more potent in inducing cell spreading than rFN(C) (Fig. 3B). Similarly, cellular FN was more active than plasma FN in inducing cell spreading, although the difference between cellular and plasma FNs was less evident than between rFN(AC) and rFN(C). No significant difference was found, however, between rFN(AC) and rFN(BAC), indicating that the insertion of the EDB segment did not affect the cell spreading activity of EDA+ FN isoforms. Enhanced cell spreading onto EDA+ FN-coated substrates was also observed with other cell lines including rat NRK cells, mouse L cells, and hamster CHO-K1 cells (data not shown).

The greater cell-adhesive activity of the EDA-containing isoforms was not an artifact because of variation in quantities of FNs adsorbed onto the substrata, since equal adsorption of FNs onto plastic surfaces was confirmed by: (a) ELISA using different mAbs directed to conserved FN epitopes, and (b) extraction of the substrate-bound FNs.
Figure 4. Dose dependence of the spreading of HT1080 cells on recombinant FNs. HT1080 cells were seeded on plates coated with various concentrations of rFN(C) (open circles), rFN(AC) (closed circles), or rFN(BAC) (closed squares) and incubated for 30 min at 37°C. Spreading of HT1080 cells was quantified as described in Materials and Methods and expressed as the number of cells adopting a well spread morphology per square millimeter. Each bar represents the mean ± SD (n = 3).

In support of this conclusion, function-blocking mAbs directed against the integrin α5 or β1 subunits inhibited spreading of HT1080 cells onto the rFN(AC)-coated substrates almost completely, whereas the mAbs directed against other types of FN-binding integrins, i.e., anti-α4 and anti-αvβ3 mAbs, were barely inhibitory (Fig. 6). These results indicated that spreading of HT1080 cells onto rFN(AC)-coated substrates was predominantly mediated by interaction of integrin α5β1 with CCBD, as was the case with spreading onto plasma FN-coated substrates (Aota et al., 1991). This conclusion was further supported by the observation that GRGDS peptide, but not GRGESP, inhibited almost completely rFN(AC)-mediated spreading of HT1080 cells (Fig. 6). These results, together with the failure of EDA antagonists to inhibit rFN(AC)-mediated cell spreading, indicated that the EDA segment augments the cell-adhesive activity of FNs by promoting the interaction of integrin α5β1 with the RGD-containing CCBD and not by providing an additional cell-interactive site.

Enhanced Cell Adhesive Activity of EDA+FN Is Independent of Cell Surface Heparan Sulfate

Interaction of the heparin-binding domain of FN with cell
surface heparan sulfate has been shown to promote integrin α5β1-mediated cell spreading on FN-coated substrates (Woods et al., 1986). To examine the possible involvement of surface heparan sulfate in enhanced cell spreading onto EDA+ FN-coated substrates, HT1080 cells were treated with heparitinase I before incubation on FN-coated substrates. FACS® analysis using the anti-heparan sulfate mAb HepSS-1 showed that >95% of heparan sulfate on the cell surface was removed by heparitinase treatment (data not shown). The removal of surface heparan sulfate, however, did not significantly affect the spreading of HT1080 cells on substrates coated with either rFN(AC) or rFN(C) (Fig. 7). A similar result was obtained when CHO803 cells that are deficient in surface heparan sulfate (Esko et al., 1988) were used for the cell spreading assay (data not shown), confirming that cell surface heparan sulfate is apparently not involved in enhanced cell spreading seen on rFN(AC)-coated substrates.

**Increased Affinity of Integrin α5β1 to EDA+ FN**

The results described above left us with the possibility that the binding affinity of integrin α5β1 to CCBD could be enhanced by inclusion of the EDA segment. To explore this possibility further, integrin α5β1 purified from human placenta and reconstituted into phosphatidylycholine liposomes containing [3H]dipalmitoyl phosphatidylycholine was tested for its binding avidity to recombinant FNs with or without the EDA segment. As depicted in Fig. 8, integrin α5β1 liposomes bound to rFN(AC) significantly more avidly than to rFN(C). Binding of integrin α5β1 liposomes to rFN(AC) was blocked by the anti-integrin α5 mAb 8F1, as was the case with the binding to rFN(C). No significant binding was observed with vitronectin, confirming that the purified α5β1 used in this study was devoid of other integrins capable of binding to both FN and vitronectin (i.e., αvβ3, αvβ5, αvβ6, and αIIbβ3).

Binding of integrin α5β1 to FN has been shown to depend on both the RGD motif in the III10 module and the synergy site in III9 (Aota et al., 1991). Thus, enhanced binding of integrin α5β1 to rFN(AC) could conceivably be due to increased affinity of the integrin to either the RGD motif or the synergy site. To examine which site was responsible for the enhanced affinity of rFN(AC) towards α5β1, association of integrin αvβ3 with rFN(AC) or rFN(C) was examined. Binding of αvβ3 to FN has been shown to depend on the RGD motif in the III10 module; but not on the synergy site in the III9 module (Danen et al., 1995). Integrin αvβ3 purified from placenta and reconstituted in liposomes bound more avidly to rFN(AC) than to rFN(C), as was the case with α5β1 (Fig. 9). The binding was reproducibly inhibited by the anti-αvβ3 mAb LM609 and by GRGDSP peptide, but not by the anti-α5 mAb 8F1 or the control GRGESP peptide. Residual binding of αvβ3-liposomes to rFN(AC) in the presence of LM609 could result from the presence of αvβ5, another vitronectin-binding integrin, in the purified αvβ3 preparation. These results are consistent with the model that enhanced binding of integrin α5β1 to EDA+ FN is due to an increase in the affinity of α5β1 for the RGD motif in CCBD and that this increased affinity may result from an altered conformation or accessibility of CCBD in the presence of the EDA segment.

**EDA-mediated Enhancement of Integrin Binding Is Not Observed with FN Fragments**

The EDA segment may alter the conformation of CCBD...
Table 1 shows the results of the limited proteolysis experiments. The integrin-binding activity of rFN(C) was significantly increased after limited proteolysis, reaching a level comparable to that of rFN(AC) after thermolysin digestion (Fig. 10A). It was also noted that the integrin-binding activity of rFN(AC) was slightly decreased after limited proteolysis. These results do not fit with the first possibility based on the neighboring effects of the inserted EDA segment on the III10 module but rather support the second model that insertion of the EDA segment potentiates integrin binding to CCBD by altering the global conformation of the FN molecule, thereby either increasing integrin accessibility to CCBD or optimizing the local conformation of the RGD-containing III10 module by perturbing the constraints applied to CCBD.

Figure 8. Binding of integrin α5β1 to recombinant FNs. Integrin α5β1 was purified from human placenta and reconstituted in phosphatidylcholine liposomes as described in Materials and Methods. The integrin α5β1-liposomes were added to microtiter plates precoated either with 20 μg/ml of rFN(C) (open bars) or rFN(AC) (closed bars), or with 5 μg/ml of vitronectin (hatched bars) in the presence or absence of the anti-integrin α5 mAb 8F1 (10 μg/ml) and incubated for 6 h at room temperature. Quantities of bound integrin α5β1 liposomes are expressed as percentage of the total input radioactivity after subtraction of the radioactivity bound to plates coated only with BSA. Each bar represents the mean ± SD (n = 6).

To explore the second possibility further, we expressed in bacteria recombinant FN fragments containing CCBD and the Hep2 domain with or without the inserted EDA segment and examined their binding to purified integrin α5β1. Integrin α5β1 bound equally well to both recombinant CCBD-Hep2 fragments with and without the EDA segment (designated GST-CH and GST-CAH; Fig. 10B). The integrin binding to these fragments was completely inhibited by the anti-integrin α5 mAb 8F1, confirming the specificity of this binding assay. The recombinant CCBD-Hep2 fragments with and without the EDA segment were also equally active in promoting spreading of HT1080 cells (data not shown). These results provide further support for the conclusion that the EDA segment upregulates the integrin binding activity of CCBD through alteration of global conformation of the FN molecule (see Discussion). It should also be noted that no significant difference was detected in the integrin-binding activities of recombinant CCBD fragments with and without the Hep2 domain, indicating that the binding of CCBD to integrin α5β1 is independent of the adjacent Hep2 domain.

**EDA⁺ FN Is More Active than EDA⁻ FN in Promoting Cell Migration**

FN is known to promote cell migration via interaction with integrin α5β1 (Yamada et al., 1990). Increased binding avidity of integrin α5β1 for EDA⁺ FN may, therefore, lead to an enhanced cell motility on substratum coated with EDA⁺ FN. To test this possibility, migration of HT1080 cells on the substrates coated with EDA⁺ or EDA⁻ FNs were compared (Fig. 11A). HT1080 cells were significantly more migratory on rFN(AC) and rFN(BAC) than on rFN(C). No significant cell migration was observed on substrates coated with poly-L-lysine (data not shown). Quantitation of outward cell migration showed that HT1080 cells migrated 1.7–2 times farther on sub-

---

*The Journal of Cell Biology, Volume 139, 1997* 302
and Kennedy, 1979). Failure to detect differences in their cell-adhesive activities (Yamada et al., 1977), no significant differences in molecular properties such as posttranslational modification (Fukuda et al., 1982; Paul and Hynes, 1984) and solubility (Yamada et al., 1977), no significant differences in the molecular structure of the recombinant FNs, however, showed no difference between EDA⁺ and EDA⁻ isoforms. The apparent discrepancy between this report and our present study could be due to the difference in the molecular structure of the recombinant FNs used. The EDA⁺ FN used by Guan et al. (1990) did not contain the IIICS segment, whereas isoforms tested in the present study all included the complete IIICS segment, which has been shown to be critical for secretion of dimerized nascent FN polypeptides (Schwarzbauer et al., 1989). The EDA⁺ form of rat FN used by Guan et al. (1990) was predominantly secreted as monomer, whereas rFN(AC) used in the present study was secreted as dimer. It is possible that the IIICS region may be required for EDA⁻ dependent potentiating the cell-adhesive activity of FNs by ensuring dimer formation or rendering the FN molecule competent for conformational activation upon insertion of the EDA segment (see below).

Several lines of evidence indicate that the EDA segment enhances the cell-adhesive activity of FNs by increasing binding affinity to integrin α5β1 and not by providing an additional cell-adhesive site. Thus, function-blocking mAbs against CCBD or those against integrin α5β1 inhibited rFN(AC)-mediated cell spreading almost completely, while mAbs against the EDA segment showed no inhibition. Consistent with these observations, rFN(AC)-mediated cell spreading was also completely inhibited by GRGDSP peptide but not by the EDA-containing recombinant fragment. Enhanced binding affinity of EDA⁺ FN to integrin

Figure 10. Binding of integrin α5β1 to FN fragments. (A) Microtiter plates were coated with 20 μg/ml of rFN(C) (open bars) or rFN(AC) (closed bars) that had been digested with throm- lase for 0 min (Undigested) and 10 min (Digested) as described in Materials and Methods. The plates were incubated with integrin α5β1 reconstituted in phosphatidylcholine liposomes for 6 h at room temperature. Quantities of bound integrin α5β1 liposomes were expressed as percentages of the total input radioactivity after subtraction of the radioactivity bound to plates coated only with BSA. Each bar represents the mean ± SD (n = 3). (B) Microtiter plates were coated with 20 μg/ml (open bars) or 80 μg/ml (closed and hatched bars) of GST fusion proteins containing the CCBD alone (GST-C) or both the CCBD and the Hep2 domain with (GST-CAH) or without (GST-CH) the EDA segment. Integrin α5β1 liposomes were added to the plates and incubated for 6 h at room temperature. Each bar represents the mean ± SD (n = 6).

Discussion
Though expression of the alternatively spliced EDA and EDB segments of FN show spacial and temporal regulation during development, wound healing, and tumorigenesis, little is known about the function of these variable domains. In the present study, we produced three different forms of recombinant FNs differing with respect to presence or absence of the EDA and/or EDB segments and compared their adhesive functions using homogeneous proteins. Our results showed that recombinant FNs containing the EDA segment were approximately twice as potent as those lacking EDA in their abilities to promote cell adhesion and migration, irrespective of the presence or absence of another variable domain, EDB. The binding affinity of EDA⁺ FN to its integrin receptor, α5β1, was 2-2.5 times greater than that of EDA⁻ FN, indicating that alternative splicing at the EDA region regulates the binding affinity of FNs to integrin α5β1, thereby contributing to regulation of cell adhesion and migration on FN-containing extracellular matrices.

Functions of alternatively spliced EDA and EDB segments have been extensively studied by comparing the biological activities of the two forms of naturally occurring FNs, i.e., plasma and cellular FNs, only the latter of which contains substantial quantities of the EDA and/or EDB segments. Although plasma and cellular FNs differ in certain molecular properties such as posttranslational modification (Fukuda et al., 1982; Paul and Hynes, 1984) and solubility (Yamada et al., 1977), no significant differences have been found in their cell-adhesive activities (Yamada and Kennedy, 1979). Failure to detect differences in their adhesive properties could be due to heterogeneity of cellular FN used in earlier studies. Typically, cellular FN expressed in cultured fibroblasts contains as much as 50% of EDA⁻ isoforms (Magnuson et al., 1991), leaving only 25% of the entire dimer population as EDA⁺ homodimers provided that dimerization of different forms of FN polypeptides occurs stochastically. In contrast, recombinant FNs used in this study were homogeneous in terms of the presence or absence of the EDA and/or EDB segments, allowing us to demonstrate clearly enhanced cell-adhesive activity of EDA⁺ FN isoforms.

Previously, Guan et al. (1990) reported expression and isolation of various forms of rat recombinant FNs. Comparison of the cell-adhesive activity of these recombinant FNs, however, showed no difference between EDA⁺ and EDA⁻ isoforms. The apparent discrepancy between this report and our present study could be due to the difference in the molecular structure of the recombinant FNs used. The EDA⁺ FN used by Guan et al. (1990) did not contain the IIICS segment, whereas isoforms tested in the present study all included the complete IIICS segment, which has been shown to be critical for secretion of dimerized nascent FN polypeptides (Schwarzbauer et al., 1989). The EDA⁺ form of rat FN used by Guan et al. (1990) was predominantly secreted as monomer, whereas rFN(AC) used in the present study was secreted as dimer. It is possible that the IIICS region may be required for EDA⁺-dependent potentiating the cell-adhesive activity of FNs by ensuring dimer formation or rendering the FN molecule competent for conformational activation upon insertion of the EDA segment (see below).
were further incubated at 37°C for 12 h to allow them to migrate into the open space left after removal of the discs. (A) The cells were photographed before and after migration at 37°C for 12 h. The positions of the cell front before and after the cell migration were indicated by open and closed arrowheads, respectively. (B) Cell motility on different substrates was quantified by measuring the distance of outward migration, i.e., the distance between the positions of the cell front before and after cell migration. Cell motility was assayed in the presence or absence of 20 μg/ml of the anti-integrin α5 subunit mAb 8F1 or control IgG. Each bar represents the mean ± SD (n = 6).

Figure 11. Migration of HT1080 cells on recombinant FNs. 96-well plates were precoated with 5 μg/ml of rFN(C) (open bars), rFN(AC) (closed bars), or rFN(BAC) (hatched bars) and then partially covered with plastic discs (Ø 6 mm) that had been cut in half and coated with 0.01% poly-l-lysine. HT1080 cells were seeded onto the plates and incubated for 1.5 h at 37°C for 12 h to allow them to spread. The plastic discs were then removed and the cells were further incubated at 37°C for 12 h to allow them to migrate into the open space left after removal of the discs. (A) The cells were photographed before and after migration at 37°C for 12 h. The positions of the cell front before and after the cell migration were indicated by open and closed arrowheads, respectively. (B) Cell motility on different substrates was quantified by measuring the distance of outward migration, i.e., the distance between the positions of the cell front before and after cell migration. Cell motility was assayed in the presence or absence of 20 μg/ml of the anti-integrin α5 subunit mAb 8F1 or control IgG. Each bar represents the mean ± SD (n = 6).

α5β1 was demonstrated by a direct binding assay using integrin α5β1 purified and reconstituted into liposomes.

Previously, Xia and Culp (1994, 1995) reported that a recombinant EDA segment alone or in combination with its neighboring type III modules promoted adhesion of mouse 3T3 cells. The recombinant EDA segment was also reported to transform rat lipocytes into myofibroblasts (Jarnagin et al., 1994). These observations may suggest the presence of a specific cell surface receptor for the EDA segment, although the molecular identity of the receptor remains elusive. Despite these previous reports, we could not obtain evidence to support direct interaction of the EDA segment with cells. Our MBP fusion protein consisting of III11, EDA, and III12 modules did not have an activity to mediate cell attachment or spreading. Although the reason for this discrepancy remains to be clarified, the putative EDA receptor(s) could be expressed only in limited types of cells (e.g., 3T3 cells). It may also be possible that a tag of histidine hexamer added to the recombinant EDA fragment (Xia and Culp, 1994, 1995) could potentiate the interaction of the EDA segment with putative EDA receptor(s).

Recently, Hino et al. (1996) reported that EDA-enriched cellular FN was more potent than plasma FN in promoting adhesion of human synovial cells. Adhesion of synovial cells to EDA-enriched FN was partially inhibited by anti-Hep2 mAb and also by heparitinase treatment of the cells, suggesting that insertion of the EDA segment may enhance the cell-adhesive activity of FN by potentiating the interaction of the Hep2 domain with cell surface heparan sulfate proteoglycans. Despite these observations, our results showed that the interaction of the Hep2 domain with heparan sulfate proteoglycans was not involved in the enhanced adhesion of HT1080 cells on EDA+ FN-coated substrates, since (a) heparitinase treatment did not affect cell spreading onto rFN(AC)-coated substrates; (b) glycosaminoglycan-deficient CHO cells were fully competent to reproduce the difference in the cell spreading activity seen between rFN(AC) and rFN(C); (c) none of the mAbs directed to the Hep2 domain inhibited adhesion of HT1080 cells to rFN(AC)-coated surfaces (Manabe, R., unpublished observation). Although the reason for this discrepancy is not clear, the role of the Hep2 domain in EDA+ FN-mediated cell adhesion may differ among different cell types, synovial cells being strongly dependent on the interaction of the Hep2 domain with heparan sulfate proteoglycans. Since the inhibition of synovial cell adhesion by anti-Hep2 mAb and by heparitinase treatment was only partial (Hino et al., 1996), it is likely that enhanced integrin binding due to the inserted EDA segment was also involved in increased synovial cell adhesion onto EDA-enriched FN.

There are several possible mechanisms that may explain enhanced integrin-binding affinity of EDA+ FNs. First, the EDA segment might directly interact with integrins α5β1 and αvβ3, thereby synergizing with the binding of the RGD motif to these integrins (ffrench-Constant, 1995). This possibility seems unlikely, however, since binding of integrin α5β1 to the GST-fusion protein consisting of CCBD and the Hep2 domain was not affected by the presence or absence of the EDA segment. A second possibility is that insertion of the EDA segment alters the conformation of the neighboring type III modules including...
III₁₀₀, thereby enhancing the integrin-binding affinity of CCBD (ffrench-Constant, 1995). Analyses of the three-dimensional structure of a recombinant FN fragment consisting of III₇–III₁₀ modules revealed that two adjacent type III modules are interconnected with tilts and rotations along the long axis (Leahy et al., 1996). Insertion of an extra type III module (i.e., the EDA module) could alter the conformation of the neighboring modules (i.e., III₁₁ and III₁₂) by readjusting the intermodular rotations and tilts, which could in turn alter the conformation of their neighboring modules including III₁₀₀ so as to optimize the conformation of the RGD-containing loop. The third possibility is that insertion of the EDA segment alters the global conformation of the FN molecule by rotating the NH₂-terminal portion of the FN polypeptide relative to the COOH terminus (Fig. 12). Given a pseudo-twofold relationship between adjacent type III modules (Huber et al., 1994; Leahy et al., 1996), the insertion of the EDA segment is expected to rotate the NH₂-terminal two-thirds (the NH₂ terminus through III₁₁) up to 180° relative to the COOH-terminal one-third (III₁₂ through the COOH terminus). Such a change in global conformation may not only increase the accessibility of the RGD motif within CCBD to integrin α₅β₁ and/or alter the local conformation of the III₁₀ module so as to optimize the binding of integrin α₅β₁ to the RGD motif. Arrowheads point to the position of the EDA insertion.

The proposed EDA-induced change in the global conformation of FN is further supported by the following distinctions between the EDA⁺ and EDA⁻ FN isoforms. Cellular FN containing EDA and/or EDB segments has been shown to be much less soluble than plasma FN under physiological buffer conditions (Yamada et al., 1977). Altered solubility can be easily explained by changes in global conformation that may increase the exposure of hydrophobic and/or charged surfaces of the FN molecule. Furthermore, alteration in global conformation may be compatible with an increased matrix assembly of the EDA⁺ FN isoforms. Guan et al. (1990) reported that EDA⁺ isoforms were
more readily incorporated into the extracellular matrix than an isofrom lacking both EDA and EDB segments. We also found that rFN(AC) is 2-3-fold more efficient than rFN(C) in assembling into the extracellular matrix (Manabe, R., unpublished observation). Although the molecular mechanisms for FN matrix assembly remain to be elucidated, FNs are considered to undergo a conformational change from a compact to an extended conformation upon binding to integrin receptors on cell surfaces, thereby dissociating intramolecular interactions and exposing sites for FN–FN interaction (Mosher, 1993; Sechler et al., 1996). The EDA-mediated conformational change may accelerate FN matrix assembly by facilitating the conformational activation of FNs upon binding to RGD-dependent integrins, particularly α5β1.

In vivo expression patterns of different FN isoforms suggest a role for EDA FN in cell growth as well as in cell migration. The EDA segment is included in FN species expressed in embryonic tissues but is spliced out of the molecule in most tissues as embryonic development progresses (Vartio et al., 1987; ffrench-Constant and Hynes, 1989). In adults, EDA FN reappears during wound healing and in tumor tissues (ffrench-Constant et al., 1989; Oyama et al., 1989a). In addition, levels of the EDA FN expression are significantly higher in invasive tumors than in noninvasive ones (Oyama et al., 1989a). Since tissues where EDA FNs are highly expressed are populated with cells having high proliferative and migratory potentials, it seems likely that EDA FNs play an important role in promoting cell proliferation and migration in vivo. In support of this notion, our results show that EDA FN is more potent than EDA FN in promoting migration of HT1080 cells. Under circumstances where vast cell proliferation and migration are required, the splicing pattern at the EDA region is apparently altered to produce more EDA FN isoforms and, in so doing, to strengthen signals from the surrounding FN matrix. Regulation of extracellular signals at the level of RNA splicing represents a novel mechanism for the control of proliferation, differentiation, and apoptosis of adherent cells.

Despite the importance of the EDA segment in regulating the cell-adhesive properties of FN, the function of the EDB segment remains to be defined. Since expression of EDB FN isoforms in vivo is more restricted than that of EDA isoforms (ffrench-Constant and Hynes, 1989), the EDB segment may have an important function only in highly specific situations, such as early embryonic development. By analogy with the EDA segment, the insertion of the EDB segment is expected to alter the global conformation of the FN molecule by rotating the NH2-terminal half (i.e., NH2 terminus through IIII-) relative to the COOH terminus. Although the EDB segment did not affect the cell-adhesive activity of EDA FNs, it may modulate other biological functions of FN through conformational perturbation.

Further studies on the biological activities of a panel of recombinant FN isoforms differing with respect to presence or absence of EDA and EDB segments should provide clues to the function of the EDB segment.

We thank Dr. Keiko Ichihara-Tanaka for generous gifts of the plasmid pHC5F and pHCF93, Dr. Luciano Zardi for the mAbs IST-9 and BC-1, Hisanobu Hirano for the mAb OAL115, Eiji Sakashita for the mAb HHS01, and Dr. Masahiro Nakayama (Department of Pathology, Osaka Medical Center for Maternal and Child Health, Osaka, Japan) for allowing us to use term placenta for purification of integrins. We also thank Dr. Judith Healy for valuable comments on this manuscript.

This work was supported by the Special Coordination Fund from the Science and Technology Agency of Japan, the Grants-in-aid for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan, and a grant from Osaka Cancer Foundation.

Received for publication 12 March 1997 and in revised form 6 July 1997.

References

Aguirre, K.M., R.J. McCormick, and J.E. Schwarzbaeur. 1994. Fibronectin self-association is mediated by complementary sites within the amino-terminal one-third of the molecule. J. Biol. Chem. 269:27863–27868.

Akamatsu, H., K. Ichihara-Tanaka, K. Ozono, W. Kamikae, H. Matsuda, and K. Sekiguchi. 1996. Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. Cancer Res. 56: 4541–4546.

Akiyama, S.K., E. Hasegawa, T. Hasegawa, and K.M. Yamada. 1985. The interaction of fibronectin fragments with fibroblastic cells. J. Biol. Chem. 260: 13256–13260.

Aota, S., T. Nagai, and K.M. Yamada. 1991. Characterization of regions of fibronectin besides the arginine-glycine-aspartic acid sequence required for adhesiveness of the cell-binding domain using site-directed mutagenesis. J. Biol. Chem. 266:15938–15943.

Aota, S., M. Nomizu, and K.M. Yamada. 1994. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 269:24756–24761.

Benecky, M.J., C.G. Kolvenbach, R.W. Wine, J.P. DiOrio, and M.W. Moseson. 1990. Human plasma fibronectin structure probed by steady-state fluorescence polarization: evidence for a rigid oblate structure. Biochemistry. 29: 3082–3091.

Borsl, L., B. Carmelonna, P. Catellani, C. Rossellini, D. Vecchio, G. Allemani, S.E. Chang, J. Taylor-Papadimitriou, H. Pande, and L. Zardi. 1987. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed cells. J. Cell Biol. 104:595–600.

Bowditch, R.D., M. Harharian, E.F. Tommina, J.W. Smith, K.M. Yamada, E.D. Giancotti, and M.H. Ginsberg. 1994. Identification of a novel binding site in fibronectin: differential utilization by β3 integrins. J. Biol. Chem. 269:10856–10863.

Carmelonna, B., E. Balza, A. Sira, L. Zardi, M.R. Nicotra, A. Bigotti, and P.G. Natali. 1989. A tumor-associated fibronectin isofrom generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108:1139–1148.

Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745–2752.

Chen, J., T. Maeda, K. Sekiguchi, and D. Sheppard. 1996. Distinct structural requirements for interaction of the integrins α5β1, αvβ5, and αvβ6 with the central cell-binding domain in fibronectin. Cell Adhes. Commun. 4:237–250.

Danan, E.H.J., S. Aota, A.A. van Kraats, K.M. Yamada, D.J. Ruiter, and M.G.P. van Muijen. 1995. Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin α5β1. J. Biol. Chem. 270:21612–21618.

Erkicck, H.P. 1994. Reversible unfolding of fibronectin type III and immuno-globulin domains provides the structural basis for anchorage and elasticity of titin and fibronectin. Proc. Natl. Acad. Sci. USA. 91:10114–10118.

Erkicck, H.P., and N.A. Carrell. 1983. Fibronectin in extended and compact conformations: electron microscopy and sedimentation analysis. J. Biol. Chem. 258:14539–14544.

Esco, J.D., K.S. Rostand, J.L. Weincke. 1988. Tumor formation dependent on proteoglycan biosynthesis. Science (Wash. DC). 241:1092–1096.

ffrench-Constant, C. 1995. Alternative splicing of fibronectin: many different proteins but few different functions. Exp. Cell Res. 221:261–271.

ffrench-Constant, C., and R.O. Hynes. 1989. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development. 106:375–388.

ffrench-Constant, C., L. Van De Water, H.F. Dvorak, and R.O. Hynes. 1989. Appearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 109:903–914.

Fukuda, M., S.B. Livery, and S. Hakomori. 1982. Carbohydrate structure of hamster plasma fibronectin: evidence for chemical diversity between cellular and plasma fibronectins. J. Biol. Chem. 257:6856–6860.

George, E.L., E.N. Georges-Labouesse, R.S. Patel-King, H. Rayburn, and R.O. Hynes. 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 119:1079–1091.

Giancotti, F.G., and E. Ruoslahti. 1990. Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 60:849–859.

Gian, J.-Y., J.E. Trevithick, and R.O. Hynes. 1990. Retroviral expression of alternatively spliced forms of rat fibronectin. J. Cell Biol. 110:833–847.

Hayashi, M., and K.M. Yamada. 1983. Domain structure of the carboxy-terminal half of human plasma fibronectin. J. Biol. Chem. 258:3332–3340.

The Journal of Cell Biology, Volume 139, 1997 306
Huber, A.H., Y.E. Wang, A.J. Bieber, and P.J. Bjorkman. 1994. Crystal structure of the integrin-binding III-10 module in fibronectin matrix assembly. J. Cell Biol. 133:431–444.

Hynes, R.O. 1990. Fibronectins. Springer-Verlag, New York. 546 pp.

Jarnagin, W.R., D.C. Rockey, V.E. Koteliansky, S. Wang, and D.M. Bissell. 2008. Integrin VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J. Cell Biol. 185:1343–1354.

Kaufman, R.J. 1989. Selection and coamplification. Methods Enzymol. 185:537–566.

Kornblitt, A.R., K. Vibe-Pedersen, and F.E. Baralle. 1984. Human fibronectin: cell specific alternative mRNA splicing generates polypeptide chains differing in the number of internal repeats. Nucl. Acids Res. 12:5853–5868.

Kornblitt, A.R., K. Umezawa, K. Vibe-Pedersen, and F.E. Baralle. 1985. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J. 4:1759–1759.

Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond.). 227:680–685.

Leahy, D.J., I. Aukhil, and H.P. Erickson. 1996. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell. 84:155–164.

Magnuson, V.L., M. Young, D.G. Schattenberg, M.A. Mancini, D. Chen, B. Steffensen, and R.J. Klebe. 1991. The alternative splicing of fibronectin pre-mRNA is altered during aging and in response to growth factors. J. Biol. Chem. 266:14645–14662.

Matsuyma, S., K. Ichihara-Tanaka, and K. Sekiguchi. 1994. Targeting of the immunoglobulin-binding domain of protein A to the extracellular matrix using a mini-fibronectin expression vector. J. Biochem. 116:898–904.

Meredith, J.E., Jr., B. Fazel, and M.A. Schwartz. 1993. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4:953–961.

Miyake, K., Y. Yasunuma, H. Yagitaka, and M. Kimoto. 1992. Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J. Cell Biol. 119:653–662.

Mosher, D.F. 1993. Assembly of fibronectin into extracellular matrix. Curr. Opin. Struct. Biol. 3:214–222.

Müller, U., B. Bossy, K. Venstrom, and L.F. Reichardt. 1995. Integrin α8β1 promotes attachment, cell spreading and neurite outgrowth on fibronectin. Mol. Biol. Cell. 6:433–448.

Oyama, F., S. Hirohashi, Y. Shimosato, K. Titi, and K. Sekiguchi. 1989a. De-regulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J. Biol. Chem. 264:10331–10334.

Oyama, F., Y. Murata, N. Suganuma, T. Kimura, K. Titi, and K. Sekiguchi. 1989b. Patterns of alternative splicing of fibronectin pre-mRNA in human adult and fetal tissues. Biochemistry. 28:1426–1434.

Oyama, F., S. Hirohashi, M. Sakamoto, K. Titi, and K. Sekiguchi. 1993. Coordinate oncoedvelopmental modulation of alternative splicing of fibronectin-pre-mRNA at ED-A, ED-B, and CSI regions in human liver tumors. Cancer Res. 53:2005–2011.

Paul, J.I., and R.O. Hynes. 1984. Multiple fibronectin subunits and their post-translational modifications. J. Biol. Chem. 259:13477–13487.

Pytela, R., M.D. Pierschbacher, S. Argraves, S. Suzuki, and E. Ruoslahti. 1987. Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol. 144:475–489.

Ruoslahti, E., and M.D. Pierschbacher. 1987. New perspectives in cell adhesion: RGD and integrins. Science (Wash. DC). 238:491–497.

Schwarzbauer, J.E., J.W. Tamkun, J.R. Lemischka, and R.O. Hynes. 1983. Three different fibronectin mRNA arise by alternative splicing within the coding region. Cell. 35:421–431.

Schwarzbauer, J.E., R.S. Patel, D. Fonda, and R.O. Hynes. 1987. Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J. 6:2573–2580.

Schwarzmuhr, J.E., C.S. Spencer, and C.L. Wilson. 1989. Selective secretion of alternatively spliced fibronectin variants. J. Cell Biol. 109:3445–3453.

Sechler, J.L., Y. Takada, and J.E. Schwarzbauer. 1996. Altered rate of fibronectin mRNA assembly by deletion of the first type III repeats. J. Cell Biol. 134:573–583.

Sekiguchi, K., and K. Titi. 1989. Probing molecular polymorphism of fibronectins with antibodies directed to the alternatively spliced peptide segments. Biochemistry. 28:3293–3298.

Williams, E.C., P.A. Janney, J.D. Ferry, and D.F. Mosher. 1982. Conformational states of fibronectin: effects of pH, ionic strength, and collagen binding. J. Biol. Chem. 257:14973–14978.

Wood, A., J.R. Couchman, S. Johansson, and M. Höök. 1986. Adhesion and cytoskeletal organization of fibroblasts in response to fibronectin fragments. EMBO (Eur. Mol. Biol. Organ.) J. 5:665–670.

Xia, P., and L.A. Culp. 1994. Adhesion activity in fibronectin’s alternatively spliced domain EDa. 213:253–265.

Xia, P., and L.A. Culp. 1995. Adhesion activity in fibronectin’s alternatively spliced domain EDa: complementarity to plasma fibronectin function. Exp. Cell Res. 217:517–527.

Yamada, K.M. 1991. Fibronectin and other cell interactive glycoproteins. In Cell Biology of Extracellular Matrix. E. Hay, editor. Plenum Press, New York. 111–146.

Yamada, K.M., and D.W. Kennedy. 1979. Fibroblast cellular and plasma fibronectins are similar but not identical. J. Cell Biol. 80:492–498.

Yamada, K.M., D.H. Schlesinger, D.W. Kennedy, and I. Pastan. 1977. Characterization of a major fibroblast cell surface glycoprotein. Biochemistry. 16:5552–5559.

Yamada, K.M., D.W. Kennedy, S.S. Yamada, H. Gralnick, W. Chen, and S.K. Akiyama. 1990. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. Cancer Res. 50:4805–4806.

Yang, J.T., J.H. Rayburn, and R.O. Hynes. 1993. Embryonic mesodermal defects in α5 integrin-deficient mice. Development. 119:1093–1105.

Zardi, L., B. Carnemolla, A. Siri, T.E. Petersen, G. Padella, G. Sebastio, and F.E. Baralle. 1987. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO (Eur. Mol. Biol. Organ.) J. 6:2337–2342.